Empagliflozin reduces cardiovascular mortality in type 2 diabetes independently of glycemic control. Which cardiac hemodynamic mechanism is primarily responsible for this benefit?

• A Direct inhibition of SGLT1 in cardiac myocytes reducing glucose-driven lipotoxicity
• B Reduction of epicardial adipose tissue via visceral fat mobilization
• C Increased erythropoietin production improving cardiac oxygen delivery
• D Osmotic diuresis and natriuresis reducing preload and afterload, along with reduced sympathetic tone and myocardial oxygen demand (hemodynamic unloading) ✓

Explanation

SGLT2 inhibitors like empagliflozin reduce glucose, sodium, and water reabsorption in the proximal convoluted tubule, producing osmotic diuresis and natriuresis. This reduces plasma volume, ventricular preload, and to a lesser extent afterload — analogous to a mild loop diuretic but without electrolyte derangements. Reduced sympathetic activity, lower blood pressure, and improved ventricular compliance contribute to cardiac protection. Additionally, increased ketogenesis may provide alternative fuel to failing myocardium. EMPA-REG OUTCOME showed 38% reduction in cardiovascular death. The erythropoiesis-stimulating effect and epicardial fat reduction are secondary mechanisms, not primary.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.